The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the injections over the next few months.
Related Posts
Amazon earnings primer: Why AI and tariffs are key to the second quarter
The earnings report will give investors a fresh look at how Amazon is navigating tariff-related uncertainty.
Meta plans to release standalone Meta AI app in effort to compete with OpenAI’s ChatGPT
Meta’s upcoming AI app advances CEO Mark Zuckerberg’s plans to make his company the leader in AI by the end of the year, people familiar […]
23andMe appoints three new board members following abrupt resignations
23andMe appointed three new independent directors to its board, the company said Tuesday.